Here, we used orthotopic HCC xenografts to show that administration of GalNAc‐ALDOA effectively slowed HCC cell growth in vivo; concomitantly, the protein level of eIF4G was decreased. The gene discussed is EIF4G1; the disease is hepatocellular carcinoma.